Silvio Inzucchi, MD

Silvio Inzucchi, MD
 

Professor of Medicine (Endocrinology)
Clinical Director, Section of Endocrinology
Director, Yale Diabetes Center
Director, Endocrinology & Metabolism Fellowship
New Haven, Connecticut


Where might the fixed ratio, combination regimens consisting of a long-acting insulin and GLP-1 RA fit into the ADA and AACE guidelines and how do your see their use in the sequencing algorithm for T2D?

Where might the fixed ratio, combination regimens consisting of a long-acting insulin and GLP-1 RA fit into the ADA and AACE guidelines and how do your see their use in the sequencing algorithm for T2D?

How would you deploy the fixed ratio combination agents in a 58-year old obese male patient who was not meeting HA1c target goals on metformin alone, or a second oral agent?

How would deploy the fixed ratio combination agents in a 58-year old obese male patient who was not meeting HA1c target goals on metformin alone, or a second oral agent?

What is the importance of PPG and glucose excursions as a management metric and what are the implications for selecting a specific GLP-1 RA with a specific PK/PD profile?

What is the importance of postprandial hyperglycemia (PPG) and glucose excursions as a management metric and what are the implications for selecting a specific GLP-1 RA with a specific PK/PD profile?

How do we assess to what degree PPG is playing a role in failing to achieve goal-directed HA1c levels? How do we use FPG and PPG to determine the need for agents for PPG control?

From a practical perspective, how do we assess to what degree PPG is playing a role in failing to achieve goal-directed HA1c levels? How do we use FPG and PPG levels to determine the need for agents useful for PPG control?

What was the physiological, safety, and compliance-focused rationale for combining basal insulin plus GLP-1 RA into a fixed ratio formulation?

What was the physiological, safety, and compliance-focused rationale for combining basal insulin plus GLP-1 RA into a fixed ratio formulation?